MGNX Quote, Financials, Valuation and Earnings

CorMedix, Inc. has a net margin of 23.1% compared to MacroGenics, Inc.'s net margin of 49.9%. MacroGenics, Inc.'s return on equity of -88.47% beat CorMedix, Inc.'s return on equity of 95.25%.

MacroGenics, Inc. has a consensus price target of $3.40, signalling upside risk potential of 98.83%. On the other hand CorMedix, Inc. has an analysts' consensus of $14.86 which suggests that it could grow by 102.41%. Given that CorMedix, Inc. has higher upside potential than MacroGenics, Inc., analysts believe CorMedix, Inc. is more attractive than MacroGenics, Inc..

MacroGenics, Inc. has a beta of 1.505, which suggesting that the stock is 50.537% more volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.388, suggesting its more volatile than the S&P 500 by 38.76%.

MacroGenics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MacroGenics, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.

MacroGenics, Inc. quarterly revenues are $72.8M, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. MacroGenics, Inc.'s net income of $16.8M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, MacroGenics, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 3.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MacroGenics, Inc. is 0.84x versus 2.47x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Amicus Therapeutics, Inc. has a net margin of 23.1% compared to MacroGenics, Inc.'s net margin of 10.24%. MacroGenics, Inc.'s return on equity of -88.47% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.

MacroGenics, Inc. has a consensus price target of $3.40, signalling upside risk potential of 98.83%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 1.33%. Given that MacroGenics, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe MacroGenics, Inc. is more attractive than Amicus Therapeutics, Inc..

MacroGenics, Inc. has a beta of 1.505, which suggesting that the stock is 50.537% more volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.381, suggesting its less volatile than the S&P 500 by 61.857%.

MacroGenics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MacroGenics, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.

MacroGenics, Inc. quarterly revenues are $72.8M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. MacroGenics, Inc.'s net income of $16.8M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, MacroGenics, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MacroGenics, Inc. is 0.84x versus 7.32x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of 23.1% compared to MacroGenics, Inc.'s net margin of 18.06%. MacroGenics, Inc.'s return on equity of -88.47% beat Merck & Co., Inc.'s return on equity of 39.63%.

MacroGenics, Inc. has a consensus price target of $3.40, signalling upside risk potential of 98.83%. On the other hand Merck & Co., Inc. has an analysts' consensus of $124.88 which suggests that it could grow by 2.86%. Given that MacroGenics, Inc. has higher upside potential than Merck & Co., Inc., analysts believe MacroGenics, Inc. is more attractive than Merck & Co., Inc..

MacroGenics, Inc. has a beta of 1.505, which suggesting that the stock is 50.537% more volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.280, suggesting its less volatile than the S&P 500 by 72.042%.

MacroGenics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.7% to investors and pays a quarterly dividend of $0.85 per share. MacroGenics, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

MacroGenics, Inc. quarterly revenues are $72.8M, which are smaller than Merck & Co., Inc. quarterly revenues of $16.4B. MacroGenics, Inc.'s net income of $16.8M is lower than Merck & Co., Inc.'s net income of $3B. Notably, MacroGenics, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 16.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MacroGenics, Inc. is 0.84x versus 4.68x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xencor, Inc. has a net margin of 23.1% compared to MacroGenics, Inc.'s net margin of -28.7%. MacroGenics, Inc.'s return on equity of -88.47% beat Xencor, Inc.'s return on equity of -20.07%.

MacroGenics, Inc. has a consensus price target of $3.40, signalling upside risk potential of 98.83%. On the other hand Xencor, Inc. has an analysts' consensus of $28.83 which suggests that it could grow by 148.78%. Given that Xencor, Inc. has higher upside potential than MacroGenics, Inc., analysts believe Xencor, Inc. is more attractive than MacroGenics, Inc..

MacroGenics, Inc. has a beta of 1.505, which suggesting that the stock is 50.537% more volatile than S&P 500. In comparison Xencor, Inc. has a beta of 0.980, suggesting its less volatile than the S&P 500 by 1.968%.

MacroGenics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xencor, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MacroGenics, Inc. pays -- of its earnings as a dividend. Xencor, Inc. pays out -- of its earnings as a dividend.

MacroGenics, Inc. quarterly revenues are $72.8M, which are larger than Xencor, Inc. quarterly revenues of $21M. MacroGenics, Inc.'s net income of $16.8M is higher than Xencor, Inc.'s net income of -$6M. Notably, MacroGenics, Inc.'s price-to-earnings ratio is -- while Xencor, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MacroGenics, Inc. is 0.84x versus 5.70x for Xencor, Inc.. Usually stocks with elevated PS ratios are considered overvalued.